GlassScriptPhysician profile
Doris L Wilder
NPI 1760476774
$2,867.52
in general payments reported to CMS, 2019-2025
21 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $596 · 2021: $422 · 2022: $177 · 2023: $309 · 2024: $413 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $585.63 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $426.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $303.07 | 2019-2020 | |
| Lilly USA, LLC | $272.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Ironwood Pharmaceuticals, INC | $203.98 | 2021-2023 | Linzess |
| Astrazeneca Pharmaceuticals LP | $174.86 | 2019-2024 | Airsupra |
| Glaxosmithkline, LLC. | $174.21 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $123.65 | 2019-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $116.45 | 2019-2021 | |
| Viiv Healthcare Company | $107.00 | 2024 | |
| Sunovion Pharmaceuticals INC. | $66.56 | 2021 | |
| Pfizer INC. | $61.85 | 2019-2024 | |
| Amgen INC. | $47.63 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $42.12 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.85 | 2019-2024 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $28.97 | 2024 | Ibsrela |
| Amarin Pharma, INC. | $26.39 | 2019-2020 | |
| Astellas Pharma US INC | $24.69 | 2025 | Veozah |
| Abbott Laboratories | $19.99 | 2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $16.52 | 2025 | Korlym |
| Sanofi Pasteur INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Wilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.